All In Biotech

Drug Trial Radar · NCT06257966

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

A Phase 3, Multi-center, Open-label, Randomized Study to Evaluate the Efficacy and Safety of JY09 Versus Dulaglutide in Patients With T2DM Inadequately Controlled by Metformin

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Actual

Start

Jul 17, 2024

Primary completion

Oct 1, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to compare the efficacy and safety of two JY09 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

Conditions

  • Type2 Diabetes Mellitus

Interventions

  • Exendin-4 Fc fusion protein injection(1.2mg)Drug

    1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.

  • Exendin-4 Fc fusion protein injection(2.4mg)Drug

    The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.

  • DulaglutideDrug

    1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.

  • MetforminDrug

    Metformin hydrochloride tablets, oral administration, 54 weeks of treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1cTime frame: Baseline, Week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.